Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lifitegrast

FDA-approved product (solution/drops, ophthalmic), marketed as Lifitegrast, Xiidra.

Registered studies
39
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Lifitegrast
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Dry eye syndrome
  • Eye disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other ophthalmologicals
FDA pharmacologic class
Lymphocyte Function-Associated Antigen-1 Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

39registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lifitegrast in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lifitegrast with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

    NCT04354545 · start 2021-04-01

    Registered record
    Registry ID
    NCT04354545
    Conditions
    Glaucoma; Ocular Surface Disease
    Interventions
    Xiidra (Lifitegrast ophthalmic solution) 5%
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-04-01
    Completion
    2026-12-01
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlaucoma; Ocular Surface Disease
    InterventionXiidra (Lifitegrast ophthalmic solution) 5%
    PhaseNot recorded
    Registry statusRecruiting

  • The Chronology of Lifitegrast Effect on Anterior Surface Rehabilitation (CLEAR) Study

    NCT04669561 · start 2021-03-17

    Registered record
    Registry ID
    NCT04669561
    Conditions
    Dry Eye
    Interventions
    Lifitegrast 5% Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-03-17
    Completion
    2021-10-08
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionLifitegrast 5% Ophthalmic Solution
    PhasePhase 4
    Registry statusCompleted

  • Treatment Regimens in Meibomian Gland Dysfunction

    NCT05594745 · start 2021-03-02

    Registered record
    Registry ID
    NCT05594745
    Conditions
    Dry Eye Syndromes
    Interventions
    Lifitegrast Ophthalmic; Systane Free; Lipiflow
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-03-02
    Completion
    2023-01-21
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Syndromes
    InterventionLifitegrast Ophthalmic; Systane Free; Lipiflow
    PhasePhase 4
    Registry statusCompleted

  • Effect of Lifitegrast 5% on Tear Film Markers

    NCT03952481 · start 2021-03-01

    Registered record
    Registry ID
    NCT03952481
    Conditions
    Dry Eye; Dry Eye Syndromes; Dry Eyes Chronic
    Interventions
    Lifitegrast 5% Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-03-01
    Completion
    2021-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye; Dry Eye Syndromes; Dry Eyes Chronic
    InterventionLifitegrast 5% Ophthalmic Solution
    PhasePhase 4
    Registry statusWithdrawn

  • Efficacy of Xiidra in Dry Eye Disease After Collagen Cross Linking

    NCT05045053 · start 2021-02-01

    Registered record
    Registry ID
    NCT05045053
    Conditions
    Corneal Disease
    Interventions
    Xiidra 5% Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-02-01
    Completion
    2022-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCorneal Disease
    InterventionXiidra 5% Ophthalmic Solution
    PhasePhase 4
    Registry statusUnknown

  • A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

    NCT04734197 · start 2021-01-11

    Registered record
    Registry ID
    NCT04734197
    Conditions
    Dry Eye Disease
    Interventions
    SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate); Mycophenolic Acid 0.1%; Mycophenolic Acid 0.3%; Betamethasone Sodium Phosphate 0.01%; Placebo Comparator: Vehicle; Cyclosporine 0.05% Ophthalmic Emulsion; Lifitegrast 5% Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-01-11
    Completion
    2022-03-25
    Enrolment
    349

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease
    InterventionSURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate); Mycophenolic Acid 0.1%; Mycophenolic Acid 0.3%; Betamethasone Sodium Phosphate 0.01% +3 more
    PhasePhase 2
    Registry statusCompleted

  • Xiidra vs. Xiidra + Dextenza Treatment for Dry Eye Disease

    NCT04413253 · start 2020-08-01

    Registered record
    Registry ID
    NCT04413253
    Conditions
    Dry Eye Syndromes
    Interventions
    Lifitegrast 5% Ophthalmic Solution; Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2020-08-01
    Completion
    2022-04-11
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Syndromes
    InterventionLifitegrast 5% Ophthalmic Solution; Dexamethasone Intracanalicular Insert, 0.4mg with Lifitegrast 5% Ophthalmic Solution
    PhasePhase 4
    Registry statusTerminated

  • A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

    NCT04030962 · start 2020-03-04

    Registered record
    Registry ID
    NCT04030962
    Conditions
    Dry Eye Disease; Dry Eye Syndrome
    Interventions
    AGN-242428; AGN-231868; AGN-242428 Vehicle; AGN-231868 Vehicle; Lifitegrast 5% Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2020-03-04
    Completion
    2022-03-18
    Enrolment
    292

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease; Dry Eye Syndrome
    InterventionAGN-242428; AGN-231868; AGN-242428 Vehicle; AGN-231868 Vehicle +1 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days

    NCT04172961 · start 2020-02-01

    Registered record
    Registry ID
    NCT04172961
    Conditions
    Dry Eye
    Interventions
    nanomicellular cyclosporine 0.09%; Lifitegrast
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2020-02-01
    Completion
    2022-12-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    Interventionnanomicellular cyclosporine 0.09%; Lifitegrast
    PhasePhase 4
    Registry statusUnknown

  • Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease

    NCT03408015 · start 2019-01

    Registered record
    Registry ID
    NCT03408015
    Conditions
    Ocular Discomfort; Ocular Inflammation; Dry Eye; Contact Lens Complication; Keratoconjunctivitis Sicca
    Interventions
    Lifitegrast
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2019-01
    Completion
    2019-01-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOcular Discomfort; Ocular Inflammation; Dry Eye; Contact Lens Complication +1 more
    InterventionLifitegrast
    PhasePhase 4
    Registry statusWithdrawn

  • The Effect Of Lifitegrast On Refractive Accuracy And Symptoms In Dry Eye Patients Undergoing Cataract Surgery

    NCT03866629 · start 2018-12-20

    Registered record
    Registry ID
    NCT03866629
    Conditions
    Dry Eye
    Interventions
    Lifitegrast
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-12-20
    Completion
    2019-10-29
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionLifitegrast
    PhaseNot recorded
    Registry statusCompleted

  • Use of 5.0% Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease in Contact Lens Wearers

    NCT03431272 · start 2018-11-01

    Registered record
    Registry ID
    NCT03431272
    Conditions
    Contact Lens Dry Eye
    Interventions
    Lifitegrast
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2018-11-01
    Completion
    2019-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContact Lens Dry Eye
    InterventionLifitegrast
    PhasePhase 4
    Registry statusWithdrawn

  • Eyelash Prostheses Compared to 5.0% Lifitegrast BID for Dry Eye Disease.

    NCT03691636 · start 2018-10-02

    Registered record
    Registry ID
    NCT03691636
    Conditions
    Dry Eye
    Interventions
    Eyelash prostheses; 5.0% Lifitegrast Ophthalmic Solution
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-10-02
    Completion
    2019-05-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye
    InterventionEyelash prostheses; 5.0% Lifitegrast Ophthalmic Solution
    PhaseNot applicable
    Registry statusUnknown

  • Management of Signs and Symptoms Associated With Dry Eye Disease

    NCT04015219 · start 2018-07-18

    Registered record
    Registry ID
    NCT04015219
    Conditions
    Dry Eye Syndromes
    Interventions
    Self retained cryopreserved amniotic membrane; lifitegrast ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2018-07-18
    Completion
    2020-10-05
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Syndromes
    InterventionSelf retained cryopreserved amniotic membrane; lifitegrast ophthalmic solution
    PhaseNot applicable
    Registry statusTerminated

  • Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease

    NCT03287635 · start 2018-07-01

    Registered record
    Registry ID
    NCT03287635
    Conditions
    Dry Eye Disease
    Interventions
    Corticotropin 80Unit/Ml Repository Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-07-01
    Completion
    2020-03-04
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Disease
    InterventionCorticotropin 80Unit/Ml Repository Injection
    PhasePhase 4
    Registry statusCompleted